Rossari Biotech Q3 FY26 earnings call: Revenue & Margins
Q3 FY26 earnings call: what management said on revenue, margins and capex.
- Revenue
- ₹582Cr
- +13.5% YoY
- −0.7% QoQ
- Net profit
- ₹33Cr
- +3.1% YoY
- −10.8% QoQ
- Margin
- 12%
- −1 pp YoY
- 0 pp QoQ
Guidance rank: #45 of 70 in Chemicals & Petrochemicals
See the sector's top 10 — free with your mobile number.
The short version
Export growth expected to continue outperforming domestic growth, though at a moderated pace compared to the 26% YoY seen in 9M FY26. Earnings growth expected to continue, supported by steady volume growth across business segments.
From Rossari Biotech Ltd's Q3 FY26 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- Export growth expected to continue outperforming domestic growth, though at a moderated pace compared to the 26% YoY seen in 9M FY26.
- Domestic demand, especially in textiles, remains soft but export markets like Southeast Asia, MENA, Middle East, and Turkey show promise.
- Animal Health and Nutrition (AHN) business demonstrated strong growth; expected to maintain average growth with new premix plant coming onstream.
- Ramp-up of new capacities at Dahej and Unitop to continue, with optimal utilization targeted by FY27, supporting volume growth.
- New product development and market expansion prioritized, including setting up a manufacturing facility in KSA to enhance supply chain and export reach.
2 more points from Rossari Biotech Ltd's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Rossari Biotech Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Ethoxylation capacity expansion at Unitop is on track, with balance capacity expected to come onstream in Q4 FY26.
- Non-EO based capacities for Unitop, Tristar, and Rossari are planned for the next year, phased for Q3 and Q4 FY26.
- The Saudi Arabia greenfield specialty chemicals manufacturing facility has received in-principle Board approval; initial equity infusion of $8 million approved for evaluation and groundwork, with the total capex to be determined post-assessment and formal Board approval.
2 more points from Rossari Biotech Ltd's call on capex
Create a free account to keep reading this call
Top-ranked in Chemicals & Petrochemicals
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Rossari Biotech Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
2 more points from Rossari Biotech Ltd's call on order book
Create a free account to keep reading this call
Rossari Biotech Ltd — Quarterly revenue & net profit
Rossari Biotech Ltd Q3 FY26 results — key figures
| ₹ Cr | Q3 FY26 | Q3 FY25 | YoY | Q2 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue | 582 | 513 | +13.5% | 586 | -0.7% |
| Operating profit (EBITDA) | 69 | 65 | +6.2% | 72 | -4.2% |
| Operating margin | 12% | 13% | -1 pp | 12% | 0 pp |
| Profit before tax | 43 | 42 | +2.4% | 50 | -14% |
| Net profit (PAT) | 33 | 32 | +3.1% | 37 | -10.8% |
| EPS (₹) | 5.92 | 5.73 | +3.3% | 6.66 | -11.1% |
Source: reported quarterly figures (Screener), ₹ crore.
Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹698 Cr, net profit ₹39 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Rossari Biotech's management said in earlier quarters
Others in Chemicals & Petrochemicals this season
- Neochem Bio (Q3 FY26)
Revenue for Q2 FY26 (Sept’25) stood at ₹4,583.16 Lakh. Key investor presentation takeaways from Neochem Bio Solutions Ltd's Q3 FY26 investor presentation — and
- Thirumalai Chemicals (Q3 FY26)
Q3 FY26 Revenue from Operations (INR Cr):** . Key investor presentation takeaways from Thirumalai Chemicals Ltd's Q3 FY26 investor presentation — and how it ran
- IVP (Q3 FY26)
Q3 FY26 Revenue from Operations: ₹144.97 crore . Key investor presentation takeaways from IVP's Q3 FY26 investor presentation — and how it ranks against sector
- Gujarat Alkalies (Q3 FY26)
3,144.48 Crores, down from Rs. Key investor presentation takeaways from Gujarat Alkalies & Chemicals Ltd's Q3 FY26 investor presentation — and how it ranks agai
Potential multibaggers · Q2 FY27
Potential multibaggers in Chemicals & Petrochemicals
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Rossari Biotech Ltd and 15K+ more earnings calls,
for less than your morning chai
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Rossari Biotech Ltd Q3 FY26 results?
Export growth expected to continue outperforming domestic growth, though at a moderated pace compared to the 26% YoY seen in 9M FY26. Earnings growth expected to continue, supported by steady volume growth across business segments.
What is Rossari Biotech Ltd share price analysis?
Rossari Biotech Ltd currently shows a neutral. The stock trades at a P/E of 18.5 with a market cap of ₹2,786 Cr. Investors should review the full earnings analysis for detailed insights.
Is Rossari Biotech Ltd planning capital expenditure?
Ethoxylation capacity expansion at Unitop is on track, with balance capacity expected to come onstream in Q4 FY26.
Keep Rossari Biotech Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.
